Crown buys Molecular Response's PDX business; Evotec taps ChemAxon for safety;

> R&D contractor Crown Bioscience bought Molecular Response's patient-derived xenograft business to expand its library of tumor samples. Item

> India's Siro Clinpharm has relocated its global headquarters, settling into a new office in Mumbai. News

> Evotec signed a deal to use ChemAxon's technology to ensure the proper handling of its many clinical compounds around the globe. More

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.